Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

Ka Lung Wu; Wessel Van Wieringen; Edo Vellenga; Sonja Zweegman; Henk M. Lokhorst; Pieter Sonneveld

Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

Ka Lung Wu, Wessel Van Wieringen, Edo Vellenga, Sonja Zweegman, Henk M. Lokhorst, Pieter Sonneveld

Research output: Contribution to journal › Article › Academic › peer-review

29 Citations (Scopus)

Abstract

The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.

Original language	English
Pages (from-to)	996-997
Number of pages	2
Journal	Haematologica
Volume	90
Issue number	7
Publication status	Published - Jul 2005

Keywords

Bortezomib
Herpes zoster
Multiple myeloma
Toxicity

Access to Document

http://www.mendeley.com/research/analysis-efficacy-toxicity-bortezomib-treatment-relapsed-refractory-multiple-myeloma-community-pract

Cite this

Wu, K. L., Van Wieringen, W., Vellenga, E., Zweegman, S., Lokhorst, H. M., & Sonneveld, P. (2005). Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica, 90(7), 996-997. http://www.mendeley.com/research/analysis-efficacy-toxicity-bortezomib-treatment-relapsed-refractory-multiple-myeloma-community-pract

@article{ddacf9df77e644078a507bb15b63ad48,

title = "Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice",

abstract = "The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.",

keywords = "Bortezomib, Herpes zoster, Multiple myeloma, Toxicity",

author = "Wu, {Ka Lung} and {Van Wieringen}, Wessel and Edo Vellenga and Sonja Zweegman and Lokhorst, {Henk M.} and Pieter Sonneveld",

year = "2005",

month = jul,

language = "English",

volume = "90",

pages = "996--997",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

Wu, KL, Van Wieringen, W, Vellenga, E, Zweegman, S, Lokhorst, HM & Sonneveld, P 2005, 'Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice', Haematologica, vol. 90, no. 7, pp. 996-997. <http://www.mendeley.com/research/analysis-efficacy-toxicity-bortezomib-treatment-relapsed-refractory-multiple-myeloma-community-pract>

TY - JOUR

T1 - Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

AU - Wu, Ka Lung

AU - Van Wieringen, Wessel

AU - Vellenga, Edo

AU - Zweegman, Sonja

AU - Lokhorst, Henk M.

AU - Sonneveld, Pieter

PY - 2005/7

Y1 - 2005/7

N2 - The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.

AB - The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.

KW - Bortezomib

KW - Herpes zoster

KW - Multiple myeloma

KW - Toxicity

M3 - Article

SN - 0390-6078

VL - 90

SP - 996

EP - 997

JO - Haematologica

JF - Haematologica

IS - 7

ER -